Highlights
Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer
Friday, 3 February 2012- It was well known that FL-guided TURBT could reduce the residual rate of NMIBC, but a systematic review conducted by P. Shen and colleagues suggested that it was not superior to conventional WL-guided...
Clinical nodal staging scores for bladder cancer
Monday, 30 January 2012- Radical cystectomy (RC) with pelvic lymph node dissection (LND) is the standard of care for refractory non-muscle-invasive and muscle-invasive bladder cancer. Although consensus exists on the need for...
US researchers use computer algorithm to identify bladder cancer marker
Thursday, 19 January 2012- Researchers at the Stanford University School of Medicine have used an innovative mathematical technique to find markers that effectively predict how deadly a cancer will be. The discovery, which in...
A novel role of Id-1 in regulating epithelial-to-mesenchymal transition in bladder cancer
Wednesday, 11 January 2012- Inhibitor of differentiation or DNA binding -1 (Id-1) has been shown to be increased in several types of advanced cancer, and to be associated with aggressive and metastatic abilities of cancer cells....
US study highlights need for more research with major variation in bladder cancer subtypes
Friday, 6 January 2012- Researchers are being urged to differentiate between two types of bladder cancer when they carry out studies, after a detailed trends analysis revealed significant differences between the main subtypes of...
Efficacy of perioperative gemcitabine and cisplatin vs MVAC in locally advanced bladder cancer
Thursday, 5 January 2012- O. Yeshchina and colleagues conducted a study to compare the outcomes of patients treated in the perioperative setting with methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) versus gemcitabine...
High expression of polo-like kinase 1 linked with bladder cancer recurrence and metastasis
Friday, 30 December 2011- Polo-like kinase 1 (Plk1) has been widely pursued as an oncology target because it is overexpressed in several human tumor types. To investigate whether Plk1 plays a general role in...
Randomised phase 2-3 trial: assessing gemcitabine/carboplatin and M-CAVI in advanced urothelial cancer patients
Thursday, 15 December 2011- M. De Santis and colleagues conducted the first randomised phase II/III trial comparing two carboplatin-based chemotherapy regimens in patients with urothelial cancer who are ineligible (“unfit”) for...
Upper urinary tract recurrence after radical cystectomy for BCa: incidence and risk factors
Monday, 5 December 2011- A group of Japanese researchers conducted a study to examine the incidence of and the risk factors for upper urinary tract recurrence in patients undergoing a radical cystectomy for bladder cancer, and to...















